Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
Jennifer K LueSathyen A PrabhuYuxuan LiuYulissa GonzalezAkanksha VermaPrabhjot S MundiNebiyu AbshiruJeannie M CamarilloSwasti MehtaEmily I ChenChanghong QiaoRenu NandakumarSerge CremersNeil L KelleherOlivier ElementoJennifer E AmengualPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Inhibition of EZH2 and HDAC is synergistic and leads to the dissociation of PRC2 complex. Our findings support the clinical translation of the combination of EZH2 and HDAC inhibition in EZH2 dysregulated lymphomas.